Stanley Hamilton, Head of Pathology and Laboratory Medicine at MD Anderson Cancer Center.
Listen 0:00 NCI's first clinical trial to be based on pathway not organ (4:20)
Listen 4:45 Which patients? (5:32)
Listen 10:20 Why Ion sequencing? (7:13)
Listen 17:33 Is this the future of clinical trials for cancer? (3:58)
Listen 21:31 Which pathways do you think will dominate the trial? (2:54)
It’s taken some time, but the NCI is finally sponsoring a big time clinical trial for cancer where the patients are organized by the genomic pathway that defines their cancer rather than the organ type.
"Instead of being a breast cancer trial, or a colorectal cancer trial, or the usual construct that’s been used, this one is obtaining biopsy specimens from patients with a whole variety of differing tumor types, evaluating them with a standardized platform to identify abnormalities, and then linking those abnormalities to arms in the trial with drugs targeted to those abnormalities. This is a completely new way of doing a clinical trial and becomes an important step in moving forward a precision medicine cancer therapy approach,” says today's guest, Stanley Hamilton, head of Pathology and Laboratory Medicine at MD Anderson Cancer Center.
How are the four centers participating in the trial going about selecting patients for this new trial? And what pathways does Stanley foresee dominating the trial?
Stanley’s lab has chosen to use Thermo Fisher’s Ion sequencers to characterize the patients’ genomic pathways. Why? Find out the answer to these questions in today’s interview with one of the leading PI’s for this unique clinical trial.